In a report released today, Charlie Haywood from Bank of America Securities maintained a Buy rating on Genmab A/S, with a price target of DKK2,500.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charlie Haywood has given his Buy rating due to a combination of factors including solid medium-term guidance and a rich pipeline of late-stage catalysts. Management’s FY26 outlook shows revenue only slightly below consensus but operating profit tracking above expectations, reflecting disciplined cost control and a strong financial base to fund growth.
He also sees substantial upside from three pivotal 2026 readouts for Epkinly, Rina-S and Peto, each targeting multibillion-dollar peak sales opportunities in sizable oncology markets. Despite mixed second-line Epkinly monotherapy data, he views the impact on key first- and second-line combination trials as limited, with strong prior datasets and supportive KOL feedback underpinning confidence in more than 40% potential EPS upside over the mid term.
According to TipRanks, Haywood is a 2-star analyst with an average return of 11.2% and a 25.00% success rate.
In another report released on February 16, Jefferies also maintained a Buy rating on the stock with a DKK2,650.00 price target.